{
    "organizations": [],
    "uuid": "3bf8456893c7e322016378bdb1428d7897748ad9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-basilea-start-of-clinical-phase-3/brief-basilea-start-of-clinical-phase-3-study-in-japan-idUSFWN1RV033",
    "ord_in_thread": 0,
    "title": "BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Basilea Pharmaceutica AG:\n* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T13:19:00.000+03:00",
    "crawled": "2018-04-19T14:51:50.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "basilea",
        "pharmaceutica",
        "ag",
        "basilea",
        "report",
        "start",
        "clinical",
        "phase",
        "study",
        "japan",
        "asahi",
        "kasei",
        "pharma",
        "antifungal",
        "isavuconazole",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}